High tumor mutation burden mitigates the negative impact of chemotherapy history on immune checkpoint blockade therapy

Seminars in Oncology, Journal Year: 2025, Volume and Issue: 52(2), P. 152334 - 152334

Published: March 12, 2025

Language: Английский

---

Identification of Genomic Instability-Associated LncRNAs as Potential Therapeutic Targets in Lung Adenocarcinoma

Cancers, Journal Year: 2025, Volume and Issue: 17(6), P. 996 - 996

Published: March 15, 2025

Background/Objectives: Non-small cell lung cancer (NSCLC) is the most common type of cancer, with adenocarcinoma (LUAD) as predominant subtype. Despite advancements in targeted therapies, many NSCLC patients still experience poor outcomes due to treatment resistance and disease progression. Genomic instability (GI), a hallmark defined increased tendency DNA mutations alterations, closely linked initiation, progression, therapy. Emerging evidence suggests that long non-coding RNAs (lncRNAs)—molecules longer than 200 nucleotides do not encode proteins but regulate gene expression—play critical roles biology are associated GI. However, relationship between GI lncRNA expression LUAD remains poorly understood. Methods: In this study, we analyzed transcript profiles lncRNAs mRNAs from samples The Cancer Genome Atlas (TCGA) database classified them based on their Homologous Recombination Deficiency (HRD) score. HRD score an unweighted sum three independent DNA-based measures genomic instability: loss heterozygosity, telomeric allelic imbalance, large-scale transitions. We then performed differential analysis identify were either upregulated or downregulated high scores compared those low scores. Following this, conducted correlation assess significance association both mRNAs. Results: identified 30 differentially expressed instability. Using RNA interactome sequencing experiments, found interactions GI-associated (GI-lncRNAs) (GI-mRNAs). Further investigation showed some GI-lncRNAs play regulatory functional other diseases. also have potential prognostic biomarkers, particularly when integrated stratification. specific was primary therapy response immune infiltration LUAD. Additionally, existing drugs could modulate GI-lncRNAs, offering therapeutic strategies address Conclusions: Our findings suggest serve valuable biomarkers for prognosis response. Furthermore, modulating these presents avenues

Language: Английский

---

Ivonescimab in non-small cell lung cancer: harmonizing immunotherapy and anti-angiogenesis

Expert Opinion on Biological Therapy, Journal Year: 2025, Volume and Issue: unknown

Published: March 31, 2025

Introduction Immunotherapy combined with anti-angiogenesis has become a useful strategy in cancer treatment. Ivonescimab, the first approved bispecific antibody targeting both immune checkpoint inhibition and anti-angiogenesis, represents breakthrough over conventional dual-drug combination approach. The emerging clinical evidence demonstrates promising efficacy manageable safety profile of ivonescimab treatment non-small cell lung (NSCLC), suggesting its potential role as cornerstone next generation immunotherapy.

Language: Английский

---

Biological mechanisms and immunotherapy of brain metastases in non-small cell lung cancer

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Journal Year: 2025, Volume and Issue: unknown, P. 189320 - 189320

Published: April 1, 2025

Language: Английский

---

Neoadjuvant therapy for non-small cell lung cancer and esophageal cancer

American Journal of Cancer Research, Journal Year: 2024, Volume and Issue: 14(3), P. 1258 - 1277

Published: Jan. 1, 2024

As the major malignant tumors in chest, non-small cell lung cancer (NSCLC) and esophageal (EC) bring huge health burden to human beings worldwide.Currently, surgery is still mainstay for comprehensive treatment NSCLC EC, but prognosis poor as results of recurrence distant metastasis.Neoadjuvant therapy refers a single or combined before surgery, aiming improve therapeutic effects traditional therapies.Unfortunately, clinical outcomes neoadjuvant are controversial due its apparent advantages disadvantages, different patients may respond differentially same scheme therapy, which makes it urgent necessary develop personalized individuals.Therefore, this review summarizes novel schemes strategies help significantly life quality suffering from chestrelated malignancies.

Language: Английский

---

A Review of the Molecular Determinants of Therapeutic Response in Non-Small Cell Lung Cancer Brain Metastases

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(13), P. 6961 - 6961

Published: June 26, 2024

Lung cancer is a leading cause of cancer-related morbidity and mortality worldwide. Metastases in the brain are common hallmark advanced stages disease, contributing to dismal prognosis. can be broadly classified as either small cell lung (SCLC) or non-small (NSCLC). NSCLC represents most predominant histology subtype cancer, accounting for majority cases. Recent advances molecular genetics, coupled with innovations molecule drug discovery strategies, have facilitated both classification precision targeting based on oncogenic driver mutations. Furthermore, these precision-based strategies demonstrable efficacy across blood-brain barrier, positive outcomes patients metastases. This review provides an overview clinical features metastases, well mechanisms that drive oncogenesis. We also explore how medicine-based leveraged improve

Language: Английский

---

Cost-effectiveness of first-line immunotherapy for advanced non-small cell lung cancer with different PD-L1 expression levels: A comprehensive overview

Critical Reviews in Oncology/Hematology, Journal Year: 2023, Volume and Issue: 193, P. 104195 - 104195

Published: Nov. 4, 2023

Language: Английский

---

Immunotherapy Is a Good Standard Option for Patients With Malignant Pleural Mesothelioma, Despite the Real-World Results From Australia

Journal of Thoracic Oncology, Journal Year: 2024, Volume and Issue: 19(4), P. 547 - 550

Published: April 1, 2024

Language: Английский

---

From bench to bedside: an interdisciplinary journey through the gut-lung axis with insights into lung cancer and immunotherapy

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Sept. 5, 2024

This comprehensive review undertakes a multidisciplinary exploration of the gut-lung axis, from foundational aspects anatomy, embryology, and histology, through functional dynamics pathophysiology, to implications for clinical science. The bidirectional communication pathway, is central understanding interconnectedness gastrointestinal- respiratory systems, both which share embryological origins engage in continuous immunological crosstalk maintain homeostasis defend against external noxa. An essential component this axis mucosa-associated lymphoid tissue system (MALT), orchestrates immune responses across these distant sites. delves into role gut microbiome modulating interactions, highlighting how microbial dysbiosis increased permeability ("leaky gut") can precipitate systemic inflammation exacerbate conditions. Moreover, we thoroughly present implication oncological practice, particularly lung cancer development response immunotherapies. Our work seeks not only synthesize current knowledge spectrum science related but also inspire future interdisciplinary research that bridges gaps between basic application. ultimate goal was underscore importance holistic advocating an integrated approach unravel its complexities human health disease.

Language: Английский

---

Gut metatranscriptomics based de novo assembly reveals microbial signatures predicting immunotherapy outcomes in non-small cell lung cancer

Journal of Translational Medicine, Journal Year: 2024, Volume and Issue: 22(1)

Published: Nov. 19, 2024

Advanced-stage non-small cell lung cancer (NSCLC) poses treatment challenges, with immune checkpoint inhibitors (ICIs) as the main therapy. Emerging evidence suggests gut microbiome significantly influences ICI efficacy. This study explores link between and outcomes in NSCLC patients, using metatranscriptomic (MTR) signatures. We utilized a de novo assembly-based MTR analysis on fecal samples from 29 patients undergoing therapy, segmented according to progression-free survival (PFS) into long (> 6 months) short (≤ PFS groups. Through RNA sequencing, we employed Trinity pipeline for assembly, MMSeqs2 taxonomic classification, DESeq2 differential expression (DE) analysis. constructed Random Forest (RF), Support Vector Machine (SVM), Extreme Gradient Boosting (XGBoost) machine learning (ML) algorithms comprehensive microbial profiles. detected no significant differences concerning alpha-diversity, but revealed biologically relevant separation two patient groups beta-diversity. Actinomycetota was overrepresented (vs PFS, 36.7% vs. 5.4%, p < 0.001), Euryarchaeota (1.3% 0.002%, = 0.009), while Bacillota showed higher prevalence group (66.2% 42.3%, 0.007), when comparing abundance of corresponding reads. Among 120 DEGs identified, cluster clearly separated large set genes more active smaller patients. Protein Domain Families (PFAMs) were analyzed identify pathways enriched Pathways related DNA synthesis Translesion metabolism-related E. coli-derived PFAMs dominated PFS. RF, SVM XGBoost ML models all confirmed predictive power our selected RNA-based signature, ROC AUCs greater than 0.84. Multivariate Cox regression tested clinical confounders PD-L1 chemotherapy history underscored influence n key biomarkers According specific signatures' associate treated outcomes. Specific gene clusters taxa might differentiate vs

Language: Английский

---